e-Therapeutics is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company’s discovery activity is in immuno-oncology and addressing drug resistance in targeted cancer therapies. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery.

e-Therapeutics is also advancing its most promising programmes through clinical trials. There is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The Company also has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400 and Hedgehog pathway inhibition.

The Company is fully funded to advance its existing development programmes in cancer and depression and a further programme from its discovery platform. It is based at sites in Oxford and Newcastle, UK.

The Company is listed on the AIM market of the London Stock Exchange (ticker ETX).

Significant shareholdings

  • Invesco – 84,524,060 (31.99%)
  • Woodford Asset Management – 46,807,479 (17.7%)
  • Aviva – 44,073,702 (16.7%)
  • Henderson Group plc– 26,445,958 (10.0%)
  • Malcolm Young – 20,644,958 (7.8%)
  • Octopus Group – 11,097,658 (4.2%)

Read more shareholder information.